AIM: Sarcosine has been identified as a differential metabolite that is greatly increased during progression from normal tissue to prostate cancer and metastatic disease. In this study we assessed the role of serum sarcosine in metastatic castration-resistant prostate cancer (mCRPC) patients. PATIENTS & METHODS: Data from 52 mCRPC patients treated with docetaxel-based chemotherapy were retrospectively analyzed. Receiver operating characteristic curves, and Kaplan-Meier and Cox multivariate analyses were performed. RESULTS: Median sarcosine values were significantly higher in mCRPC versus non-mCRPC patients (0.81 vs 0.52 nmol/µl; p < 0.0001). A significant correlation resulted between serum sarcosine levels and the duration of hormone sensitivity (Spearman's correlation coefficient: -0.51; p = 0.001). At multivariate analysis sarcosine was an independent prognostic factor of outcome in terms of overall and progression-free survival. CONCLUSION: Serum sarcosine values were significantly increased in patients with metastatic disease. Moreover, this biomarker is a risk factor for progression and survival in chemotherapy-treated mCRPC patients.
AIM: Sarcosine has been identified as a differential metabolite that is greatly increased during progression from normal tissue to prostate cancer and metastatic disease. In this study we assessed the role of serum sarcosine in metastatic castration-resistant prostate cancer (mCRPC) patients. PATIENTS & METHODS: Data from 52 mCRPC patients treated with docetaxel-based chemotherapy were retrospectively analyzed. Receiver operating characteristic curves, and Kaplan-Meier and Cox multivariate analyses were performed. RESULTS: Median sarcosine values were significantly higher in mCRPC versus non-mCRPC patients (0.81 vs 0.52 nmol/µl; p < 0.0001). A significant correlation resulted between serum sarcosine levels and the duration of hormone sensitivity (Spearman's correlation coefficient: -0.51; p = 0.001). At multivariate analysis sarcosine was an independent prognostic factor of outcome in terms of overall and progression-free survival. CONCLUSION: Serum sarcosine values were significantly increased in patients with metastatic disease. Moreover, this biomarker is a risk factor for progression and survival in chemotherapy-treated mCRPC patients.
Authors: Giuseppe Lucarelli; Pasquale Ditonno; Carlo Bettocchi; Antonio Vavallo; Monica Rutigliano; Vanessa Galleggiante; Angela Maria Vittoria Larocca; Giuseppe Castellano; Loreto Gesualdo; Giuseppe Grandaliano; Francesco Paolo Selvaggi; Michele Battaglia Journal: Dis Markers Date: 2014-02-17 Impact factor: 3.434
Authors: Luigi Cormio; Giuseppe Lucarelli; Oscar Selvaggio; Giuseppe Di Fino; Vito Mancini; Paolo Massenio; Francesco Troiano; Francesca Sanguedolce; Pantaleo Bufo; Giuseppe Carrieri Journal: Medicine (Baltimore) Date: 2016-02 Impact factor: 1.889
Authors: Hanna E Röhnisch; Cecilie Kyrø; Anja Olsen; Elin Thysell; Göran Hallmans; Ali A Moazzami Journal: BMC Med Date: 2020-07-23 Impact factor: 8.775
Authors: Giuseppe Lucarelli; Monica Rutigliano; Francesca Sanguedolce; Vanessa Galleggiante; Andrea Giglio; Simona Cagiano; Pantaleo Bufo; Eugenio Maiorano; Domenico Ribatti; Elena Ranieri; Margherita Gigante; Loreto Gesualdo; Matteo Ferro; Ottavio de Cobelli; Carlo Buonerba; Giuseppe Di Lorenzo; Sabino De Placido; Silvano Palazzo; Carlo Bettocchi; Pasquale Ditonno; Michele Battaglia Journal: Medicine (Baltimore) Date: 2015-11 Impact factor: 1.817